N, N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES

WIPO Patent Application WO2003040096

A3

Disclosed are compounds of the formula (I), wherein the variables RN, RC, R1, R25, R2, and R3 are as defined herein. These compounds have activity as inhibitors of betasecretase and are therefore useful in treating a variety of discorders such as Alzheimer's Disease.

JOHN VARGHESE (US)
MAILLARD MICHEL (US)
JAGODZINSKA BARBARA (US)
BECK JAMES P (US)
GAILUNAS ANDREA (US)
FANG LARRY (US)
SEALY JENNIFER (US)
TENBRINK RUTH (US)
FRESKOS JOHN (US)
MICKELSON JOHN (US)
SAMALA LAKSHMAN (US)
HOM ROY (US)

PCT/US2002/036072

May 06, 2004

November 08, 2002

Click for automatic bibliography generation  

ELAN PHARM INC (US)
UPJOHN CO (US)
JOHN VARGHESE (US)
MAILLARD MICHEL (US)
JAGODZINSKA BARBARA (US)
BECK JAMES P (US)
GAILUNAS ANDREA (US)
FANG LARRY (US)
SEALY JENNIFER (US)
TENBRINK RUTH (US)
FRESKOS JOHN (US)
MICKELSON JOHN (US)
SAMALA LAKSHMAN (US)
HOM ROY (US)

A61K31/164; A61K31/18; A61K31/27; C07D295/16; A61K31/336; A61K31/341; A61K31/357; A61K31/36; A61K31/381; A61K31/39; A61K31/40; A61K31/41; A61K31/415; A61K31/416; A61K31/4164; A61K31/421; A61K31/423; A61K31/426; A61K31/427; A61K31/428; A61K31/437; A61K31/439; A61K31/4402; A61K31/4409; A61K31/4418; A61K31/4439; A61K31/445; A61K31/455; A61K31/47; A61K31/495; A61P25/28; A61P43/00; C07C217/58; C07C233/36; C07C233/40; C07C233/58; C07C233/78; C07C235/20; C07C235/50; C07C235/74; C07C237/04; C07C237/06; C07C237/08; C07C237/22; C07C237/42; C07C251/38; C07C255/58; C07C271/28; C07C271/44; C07C311/08; C07C311/16; C07C311/17; C07C311/18; C07C311/19; C07C311/20; C07C311/21; C07C311/29; C07C311/37; C07C317/44; C07C317/46; C07C317/50; C07C323/60; C07C323/62; C07C323/65; C07D207/06; C07D207/08; C07D207/14; C07D207/26; C07D207/267; C07D207/27; C07D207/48; C07D209/08; C07D209/42; C07D211/10; C07D211/44; C07D211/58; C07D211/60; C07D211/96; C07D213/36; C07D213/56; C07D213/64; C07D213/71; C07D213/80; C07D213/81; C07D213/82; C07D213/85; C07D213/89; C07D215/36; C07D215/42; C07D215/48; C07D215/54; C07D215/56; C07D217/08; C07D217/22; C07D223/10; C07D231/14; C07D231/38; C07D231/56; C07D233/64; C07D233/84; C07D233/90; C07D237/14; C07D239/28; C07D239/34; C07D239/42; C07D239/48; C07D241/08; C07D241/20; C07D241/24; C07D241/44; C07D243/08; C07D249/06; C07D249/10; C07D251/46; C07D251/54; C07D257/04; C07D257/06; C07D261/08; C07D261/14; C07D261/18; C07D263/06; C07D263/32; C07D263/34; C07D263/48; C07D263/54; C07D263/56; C07D263/58; C07D265/36; C07D271/06; C07D271/08; C07D271/12; C07D275/06; C07D277/20; C07D277/30; C07D277/36; C07D277/56; C07D277/68; C07D277/82; C07D279/08; C07D279/16; C07D285/06; C07D285/10; C07D285/135; C07D295/155; C07D295/185; C07D295/192; C07D295/22; C07D295/26; C07D303/36; C07D307/20; C07D307/46; C07D307/52; C07D307/68; C07D307/84; C07D307/86; C07D307/91; C07D309/12; C07D311/04; C07D311/58; C07D317/68; C07D319/18; C07D327/06; C07D333/20; C07D333/22; C07D333/32; C07D333/34; C07D333/38; C07D333/58; C07D333/62; C07D333/68; C07D333/72; C07D335/06; C07D401/04; C07D403/04; C07D405/12; C07D409/04; C07D411/12; C07D413/04; C07D413/06; C07D413/12; C07D417/04; C07D417/12; C07D453/02; C07D471/04; C07D473/06; C07D473/08; C07D473/16; C07D487/04; C07D495/04; C07D498/04; C07D285/12; C07D; (IPC1-7): C07C215/28; C07C233/78; A61K31/13

WO1998033795A1	1998-08-06
WO2002002505A2	2002-01-10
WO2002014264A2	2002-02-21
WO2002002520A2	2002-01-10
WO2002002518A2	2002-01-10
WO2002002512A2	2002-01-10

EP0652009A1

1995-05-10

CHEVALLIER N ET AL: "CATHEPSIN D DISPLAYS IN VITRO BETA-SECRETASE-LIKE SPECIFICITY", BRAIN RESEARCH, AMSTERDAM, NL, vol. 750, no. 1/2, 1997, pages 11 - 19, XP000921314, ISSN: 0006-8993

View/Download PDF      PDF Help

Previous Patent: CRYSTALLIZATION OF POLYPROPYLENE USING A SEMI-CRYSTALLINE, BRANCHED OR COUPLED NUCLEATING AGENT

Next Patent: NITROGENOUS COMPOUNDS, PRODUCTION PROCESS, AND METHOD OF USE THEREOF